Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: firstname.lastname@example.org. Type 508 Accommodation in the subject line of e-mail.
Recommendations Regarding the Use of Vaccines That Contain Thimerosal as a Preservative
On October 20, 1999, the Advisory Committee on Immunization Practices (ACIP) reviewed information about thimerosal in vaccines and received updates from CDC's National Immunization Program and several vaccine manufacturers on the current and anticipated availability of vaccines that do not contain thimerosal as a preservative. The review was prompted by a joint statement about thimerosal issued July 8, 1999, by the American Academy of Pediatrics (AAP) and the Public Health Service (PHS) (1) and a comparable statement released by the American Academy of Family Physicians (2). These statements followed a Congressionally mandated Food and Drug Administration (FDA) review of mercury in drugs and food, which included a reassessment of the use of thimerosal in vaccines.
Thimerosal is a mercury-containing preservative that has been used as an additive in biologics and vaccines since the 1930s because it prevents bacterial and fungal contamination, particularly in multidose containers. Given the widely acknowledged value of reducing exposure to mercury, vaccine manufacturers, FDA, and other PHS agencies are collaborating to reduce the thimerosal content of vaccines or to replace them with formulations that do not contain thimerosal as a preservative as soon as possible without causing unnecessary disruptions in the vaccination system. FDA will expedite review of supplements to manufacturers' product license applications that present formulations for eliminating or reducing the mercury content of vaccines.
Hepatitis B, DTaP, and Hib Vaccines
A single-antigen, preservative-free hepatitis B vaccine (Recombivax HB[Registered], Merck & Co., Inc., West Point, Pennsylvania)* was licensed on August 27, 1999, and a second hepatitis B vaccine (Engerix-B[Registered], SmithKline Beecham Biologicals, Philadelphia, Pennsylvania) that is preservative-free is under consideration for licensure (3). One manufacturer reported that the supply of its diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine that does not contain thimerosal as a preservative would be sufficient to meet any increased demand during the next year, and three other manufacturers are developing similar DTaP vaccines that could be licensed in the future. Multiple single-antigen Haemophilus influenzae type b (Hib) vaccines and the hepatitis B/Hib combination vaccine that do not contain thimerosal as a preservative are licensed, and the supply of these products is adequate to meet national needs.
The risk, if any, to infants from exposure to thimerosal is believed to be slight. The demonstrated risks for not vaccinating children far outweigh the theoretical risk for exposure to thimerosal-containing vaccines during the first 6 months of life.
Given the availability of vaccines that do not contain thimerosal as a preservative, the progress in developing such additional vaccines, and the absence of any recognized harm from exposure to thimerosal in vaccines, hepatitis B, DTaP, and Hib vaccines that contain thimerosal as a preservative can continue to be used in the routine infant schedule beginning at age 2 months along with monovalent or combination vaccines that do not contain thimerosal as a preservative.
Reported failures to vaccinate newborns at high risk for perinatal hepatitis B virus (HBV) transmission suggest that some institutions may have misinterpreted or improperly implemented the recommendations contained in the joint statement by the AAP and PHS--and subsequent clarification-to postpone hepatitis B vaccination only for newborns who are not at high risk (1,3). Chronic HBV infection develops in approximately 90% of infants infected at birth; among chronically infected infants, the risk for premature death from HBV-related liver cancer or cirrhosis is approximately 25% (4). All hospitals and pediatric care providers should ensure that newborn infants receive hepatitis B vaccine as recommended (Table 1) (5). If the supply of single-antigen hepatitis B vaccines that do not contain thimerosal as a preservative is limited, the priority for its use should be to vaccinate newborn infants (3).
All influenza vaccines contain thimerosal; however, ACIP recommends no changes in the influenza vaccination guidelines, including those for children and pregnant women (6). Evidence suggests that children with certain medical conditions (e.g., cardiopulmonary disease, including asthma) are at substantially increased risk for complications of influenza (7,8). During the influenza season, rates of cardiopulmonary hospitalizations for otherwise healthy women in their second or third trimester of pregnancy are similar to that among persons aged greater than or equal to 65 years who do not have a chronic medical illness and for whom influenza vaccination is also recommended (9). Pregnant women with chronic medical conditions are at higher risk and have a hospitalization rate more than two times greater than among pregnant women without other high-risk medical conditions. A substantial safety margin has been incorporated into the health guidance values for organic mercury exposure developed by the Agency for Toxic Substances and Disease Registry and other agencies (10). ACIP concluded that the benefits of influenza vaccine outweigh the potential risks for thimerosal.
Note: To print large tables and graphs users may have to change their printer settings to landscape and use a small font size.
TABLE 1. Recommendations for hepatitis B vaccination of newborn infants with thimerosal-containing vaccines and vaccines that do not contain thimerosal as a preservative
* Populations or groups that have a high risk for early childhood hepatitis B virus (HBV) transmission, including Alaska Natives, Asian-Pacific Islanders, immigrant populations from countries in which HBV is of high or intermediate endemicity, and households with persons with chronic HBV infection.
Return to top.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to email@example.com.
Page converted: 11/4/1999
This page last reviewed 5/2/01